UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
---------------------------------------
Date of Report (Date of earliest event reported): February 1, 2006
NEURO-HITECH PHARMACEUTICALS, INC.
----------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 333-125699 20-4121393
---------------------------- ------------------------ ------------------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
One Penn Plaza, Suite 2514
New York, New York 10119
----------------------------------------- --------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212) 798-8100
-----------------------------------------------------------
(Former name or former address, if changed since last report)
================================================================================
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 DFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4 (c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On February 1, 2006, Neuro-Hitech Pharmaceuticals, Inc. (the "Company")
entered into an exclusive development agreement (the "Agreement") with Org Syn
Laboratory, Inc. ("Org Syn") for the development by Org Syn of synthetic
Huperzine A, in accordance with the terms of the Agreement. Org Syn is entitled
to receive an aggregate of $175,894 upon the execution of the Agreement,
$175,916 six months from the execution date and an additional $67,664 seven
months from the execution date (subject to the achievement of certain
milestones) for services rendered under the Agreement. The Agreement may be
terminated by the Company if Org Syn fails to achieve certain stated milestones.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: February 7, 2006 NEURO-HITECH PHARMACEUTICALS, INC.
By: /s/ Reuben Seltzer
------------------------------
Reuben Seltzer
President and Chief Executive
Officer
